PMID- 35700750
OWN - NLM
STAT- MEDLINE
DCOM- 20220920
LR  - 20221018
IS  - 1532-8392 (Electronic)
IS  - 0046-8177 (Linking)
VI  - 127
DP  - 2022 Sep
TI  - NR4A3 fluorescence in situ hybridization analysis in cytologic and surgical 
      specimens of acinic cell carcinoma.
PG  - 86-91
LID - S0046-8177(22)00152-6 [pii]
LID - 10.1016/j.humpath.2022.06.007 [doi]
AB  - Acinic cell carcinoma (AciCC) may pose a diagnostic challenge, particularly on 
      small biopsies and fine needle aspiration (FNA) because of its variable histology 
      including potential high-grade transformation and its mimickers. Immunoreactivity 
      with circumferential membranous staining for DOG1 can support the diagnosis of 
      AciCC but is not entirely specific. A novel rearrangement t(4;9)(q13;q31) leading 
      to up-regulation of nuclear receptor subfamily 4 group A member 3 (NR4A3) has 
      been described in AciCC, is potentially detectable by fluorescence in situ 
      hybridization (FISH) and may be useful in the evaluation for AciCC. Using NR4A3 
      Dual Color Break Apart Probe (ZytoVision, Germany) FISH was performed on AciCCs 
      from 3 large academic institutions. NR4A3 rearrangement was defined as positive 
      signal patterns in 15% of tissue interphase nuclei. Fifty-two AciCCs including 47 
      resections and 5 FNAs (including 5 paired FNA/resections) were analyzed. 
      Five non-AciCC salivary gland tumors and 2 sialadenitis cases were used as 
      controls. Eight AciCCs (15%; 8/52) failed FISH testing. FISH was positive in 23 
      AciCCs (sensitivity 59%, 23/39) with 100% concordance between 5 matched 
      resection/FNAs (3 were positive for FISH and 2 were negative). FISH was negative 
      in all non-AciCCs (specificity: 100%, 0/7). NR4A3 FISH has a sensitivity of 59% 
      and specificity of 100% in detecting AciCC, which suggests that NR4A3 
      rearrangement-driven up-regulation is a recurrent, specific oncogenic event in 
      AciCC, consistent with prior results. Hundred percent concordance between matched 
      FNA/resection samples validates its potential utility on cytology samples.
CI  - Copyright (c) 2022 Elsevier Inc. All rights reserved.
FAU - Shi, Qiuying
AU  - Shi Q
AD  - Department of Pathology and Laboratory Medicine, Emory University Hospital, 
      Atlanta GA 30308, USA.
FAU - Zhang, Bin
AU  - Zhang B
AD  - Department of Pathology and Laboratory Medicine, University of Rochester Medical 
      Center, 601 Elmwood Avenue, Box 626, Rochester, NY 14642, USA.
FAU - Bsirini, Caroline
AU  - Bsirini C
AD  - Department of Pathology and Laboratory Medicine, Emory University Hospital, 
      Atlanta GA 30308, USA.
FAU - Li, Liqiong
AU  - Li L
AD  - Department of Pathology and Laboratory Medicine, University of Rochester Medical 
      Center, 601 Elmwood Avenue, Box 626, Rochester, NY 14642, USA.
FAU - Giampoli, Ellen J
AU  - Giampoli EJ
AD  - Department of Pathology and Laboratory Medicine, University of Rochester Medical 
      Center, 601 Elmwood Avenue, Box 626, Rochester, NY 14642, USA.
FAU - Magliocca, Kelly R
AU  - Magliocca KR
AD  - Department of Pathology and Laboratory Medicine, Emory University Hospital, 
      Atlanta GA 30308, USA.
FAU - Reid, Michelle
AU  - Reid M
AD  - Department of Pathology and Laboratory Medicine, Emory University Hospital, 
      Atlanta GA 30308, USA.
FAU - Zhou, Zhongren
AU  - Zhou Z
AD  - Department of Pathology, Robert Wood Johnson Medical School and New Jersey 
      Medical School, Rutgers University, New Brunswick, NJ 08901, USA. Electronic 
      address: zz442@rwjms.rutgers.edu.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220611
PL  - United States
TA  - Hum Pathol
JT  - Human pathology
JID - 9421547
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (NR4A3 protein, human)
RN  - 0 (Receptors, Steroid)
RN  - 0 (Receptors, Thyroid Hormone)
SB  - IM
MH  - Biopsy, Fine-Needle
MH  - *Carcinoma, Acinar Cell/diagnosis/genetics/surgery
MH  - Chromosome Aberrations
MH  - DNA-Binding Proteins/genetics
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/methods
MH  - *Receptors, Steroid/genetics
MH  - Receptors, Thyroid Hormone/genetics
MH  - *Salivary Gland Neoplasms/pathology
OTO - NOTNLM
OT  - Acinic cell carcinoma
OT  - Cytomorphology
OT  - Enhancer hijacking
OT  - FISH
OT  - NR4A3
EDAT- 2022/06/15 06:00
MHDA- 2022/09/21 06:00
CRDT- 2022/06/14 19:22
PHST- 2022/05/17 00:00 [received]
PHST- 2022/05/17 00:00 [revised]
PHST- 2022/06/07 00:00 [accepted]
PHST- 2022/06/15 06:00 [pubmed]
PHST- 2022/09/21 06:00 [medline]
PHST- 2022/06/14 19:22 [entrez]
AID - S0046-8177(22)00152-6 [pii]
AID - 10.1016/j.humpath.2022.06.007 [doi]
PST - ppublish
SO  - Hum Pathol. 2022 Sep;127:86-91. doi: 10.1016/j.humpath.2022.06.007. Epub 2022 Jun 
      11.